Ologen

Olopatadine

Sterile Eye Drops

Presentation

Ologen: Each ml sterile eye drops contains Olopatadine 1 mg (as Olopatadine Hydrochloride USP).

Preservative: Benzalkonium Chloride 0.01%

Vehicle: Polyvinyl Alcohol 1.4%

Pharmacological Action

Ologen inhibits the release of histamine from the mast cell and is relatively selective histamine H_1 -antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Ologen has no effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.

Indications

Ologen eye drops are indicated for the treatment of signs and symptoms (itchy, watery, red and swollen eyes and/or eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, vernal keratitis, blepharitis, blepharoconjunctivitis and giant papillary conjunctivitis.

Dosage and Application

The recommended dose of Ologen eye drops is 1 drop in the affected eye(s) two times daily at an interval of 6 to 8 hours.

Contraindications

It is contraindicated in persons with a known hypersensitivity to any component of this product.

Side Effects

Rarely headaches have been reported. Other adverse effects: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, sinusitis and taste perversion.

Precautions

Patients should be advised not to wear a contact lens if their eye is red. Ologen should not be used to treat contact lens related irritation. Benzalkonium Chloride, preservative of this eye solution, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after instillation of Ologen eye drops before they insert their contact lenses. The treatment should be discontinued in the presence of an allergic reaction.

Drug Interactions

Specific drug interaction studies have not been conducted with Olopatadine ophthalmic solution.

Use in Pregnancy and Lactation

Ologen was found not to be teratogenic in rats and rabbits. There are, however, no adequate and well controlled studies in pregnant women. This drug should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus.

It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Ologen is administered to a nursing mother.

Over Dose

There is no information on Ologen overdose. However, excessive use of any medication can have serious consequences. If you suspect an overdose, seek medical attention without delay.

Storage Conditions

Store in a cool and dry place away from light. Keep out of reach of children. Do not touch the dropper tip to surfaces since this may contaminate the solution. After one month of the opening do not use the medicine of dropper.

Commercial Pack

Ologen : Each plastic dropper bottle containing 5 ml sterile eye drops.

Manufactured by :
GENERAL Pharmaceuticals Ltd.
Unit-2, Gazipur, Bangladesh

GENERAL Pharmaceuticals Ltd.
ISO 9001:2008 Certified Company